¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ The 10th International Congress on Lipid & Atherosclerosis (ICoLA 2021) 2ÀÏÂ÷ : 2021-09-11

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ The 10th International Congress on Lipid & Atherosclerosis (ICoLA 2021) 2ÀÏÂ÷ : 2021-09-11
±³À°ÀÏÀÚ : 2021-09-11
±³À°Àå¼Ò : ÄÜ·¡µåÈ£ÅÚ ¼­¿ï(¿Â¶óÀÎ º´Çà)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) The 10th International Congress on Lipid & Atherosclerosis (ICoLA 2021) 2ÀÏÂ÷
ÁÖÃÖ±â°ü : Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ
´ã´çÀÚ : ICoLA2021 »ç¹«±¹
¿¬¶ôó : 02-2135-3618  
À̸ÞÀÏ : secretariat@icola.org      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 700¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 23 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 100,000¿ø      
ºñ°í Àü¹®ÀÇ, ±³¼ö : 100,000¿ø / ÀüÀÓÀÇ, Àü°øÀÇ, ±ºÀÇ°ü, ¿¬±¸¿ø, Çлý µî : 4¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-12 Room 1 08:00~08:20 Interim analysis of APOLLO Study: 1 year follow-up results  Seung-Woon Rha(Korea University, Korea) 
Åä·Ð 09-12 Room 1 08:20~08:30 Discussion  () 
±³À°½Ã°£ 09-12 Room 2 08:00~08:20 How to manage vascular health with statin in Korean patient: evidence based medicine LIPILOU  Jong-Young Lee(Sungkyunkwan University, Korea) 
Åä·Ð 09-12 Room 2 08:20~08:30 Discussion  () 
±³À°½Ã°£ 09-12 Room 3 08:00~08:20 CV safety of Alogliptin in T2DM patients  Jae Hyoung Par(Korea University, Korea) 
Åä·Ð 09-12 Room 3 08:20~08:30 Discussion  () 
±³À°½Ã°£ 09-12 Room 1 09:00~09:30 Hypertriglyceridemia: diagnostic and therapeutic implications  Alan Remaley(National Institute of Health, USA) 
È޽Ġ09-12  09:30~09:40 Break  () 
±³À°½Ã°£ 09-12 Room 1 09:40~10:05 Latest data on siRNA against PCSK9  Masatsune Ogura(Chiba University Graduate School of Medicine, Japan) 
±³À°½Ã°£ 09-12 Room 1 10:05~10:30 Patient ion for PCSK9 MAb based therapies  Kausik Ray(Imperial College London, UK) 
±³À°½Ã°£ 09-12 Room 1 10:30~10:55 Biological effect & clinical benefit of omega-3 PUFA  Mi Kyung Kim(Inje University, Korea) 
Åä·Ð 09-12 Room 1 10:55~11:20 Discussion  () 
±³À°½Ã°£ 09-12 Room 2 09:40~10:05 The metabolic effects of antisense oligonucleotides treatments in dyslipidemia  Gissette Reyes-Soffer(Columbia University, USA) 
±³À°½Ã°£ 09-12 Room 2 10:05~10:30 Emerging targets for management of dyslipidemia  Hun-Jun Park(The Catholic University of Korea, Korea) 
±³À°½Ã°£ 09-12 Room 2 10:30~10:55 New PPARalpha agonist  Sang Yong Kim(Chosun University, Korea) 
Åä·Ð 09-12 Room 2 10:55~11:20 Discussion  () 
±³À°½Ã°£ 09-12 Room 3 09:40~10:05 Apolipoprotein C3 as a regulator of triglyceride-rich lipoproteins in diabetes and its complications  Jenny E. Kanter(University of Washington, USA) 
±³À°½Ã°£ 09-12 Room 3 10:05~10:30 What's new in intracellular lipid trafficking  Young Mi Park(Ewha Womans University, Kore) 
±³À°½Ã°£ 09-12 Room 3 10:30~10:55 Regulation of TG transfer protein in lipid metabolism  Mahmood Hussain(New York University, USA) 
Åä·Ð 09-12 Room 3 10:55~11:20 Discussion  () 
±³À°½Ã°£ 09-12 Room 4 09:40~10:05 Vitamin D in cardiometabolic disease - the more the better?  Yongjoo Park(Chonnam National University, Korea) 
±³À°½Ã°£ 09-12 Room 4 10:05~10:30 Systems science in biomedical research regarding obesity and noncommunicable chronic diseases  Hong Xue(George Mason University, USA) 
±³À°½Ã°£ 09-12 Room 4 10:30~10:55 Nutrition policies to improve diet and reduce health and economic burdens of cardiometabolic diseases: a microsimulation study  Yujin Lee(Myongji University, Korea) 
Åä·Ð 09-12 Room 4 10:55~11:20 Discussion  () 
±³À°½Ã°£ 09-12 Room 5 09:40~10:05 Update on pathophysiology of acute coronary syndrome  Hiroyuki Hao(Nihon University, Japan) 
±³À°½Ã°£ 09-12 Room 5 10:05~10:30 Recent studies on platelets in atherosclerosis & thrombosis  Hisanori Horiuchi(Tohoku University, Japan) 
±³À°½Ã°£ 09-12 Room 5 10:30~10:55 Latest therapeutic strategies to modify platelet function  Soon Jun Hong(Korea University, Korea) 
Åä·Ð 09-12 Room 5 10:55~11:20 Discussion  () 
È޽Ġ09-12  11:20~11:40 Break  () 
±³À°½Ã°£ 09-12 Room 1+2+3 11:40~12:10 Genetics/epigenetic approach in studies of lipid metabolism & atherosclerosis  Kiran Musunuru (University of Pennsylvania, USA) 
±³À°½Ã°£ 09-12 Room 1 12:10~12:30 Lower is better & combination is better [Ezetimibe+Rosuvastatin]  Soo Heon Kwak (Seoul National University, Korea) 
Åä·Ð 09-12 Room 1 12:30~12:40 Discussion  () 
±³À°½Ã°£ 09-12 Room 2 12:10~12:30 Are all statins the same?  Ki Hoon Han(University of Ulsan, Korea) 
Åä·Ð 09-12 Room 2 12:30~12:40 Discussion  () 
±³À°½Ã°£ 09-12 Room 3 12:10~12:30 Why should we consider Rosuvastatin + Ezetimibe fixed dose combination?  Jung-Kyu Han(Seoul National University, Korea) 
Åä·Ð 09-12 Room 3 12:30~12:40 Discussion  () 
±³À°½Ã°£ 09-12 Room 4 12:10~12:30 Controlling dyslipidemia and CV risk with Atorvastatin and Ezetimibe  Soon Jun Hong(Korea University, Korea) 
Åä·Ð 09-12 Room 4 12:30~12:40 Discussion  () 
±³À°½Ã°£ 09-12 Room 1 13:10~13:17 Treatment of enolase-1 antagonist peptide prevents atherosclerosis in LDLR KO mice  Vo Hoang Nguyet Dan(Soonchunhyang University, Korea) 
±³À°½Ã°£ 09-12 Room 1 13:17~13:24 The potential of macrophage-specific soluble Ninj1 as a therapeutic target in atherosclerosis  Sejin Jeon(Ewha Womans University, Korea) 
±³À°½Ã°£ 09-12 Room 1 13:24~13:31 Loss of the mixed lineage kinase domain-like protein decreases necrotic core but increases macrophage lipid accumulation in atherosclerosis  Adil Rasheed(University of Ottawa Heart Institute, Canada) 
±³À°½Ã°£ 09-12 Room 1 13:31~13:38 Endothelial OASL1 deficiency promotes endothelial dysfunction and atherosclerotic plaque formation  TaeKyeong Kim(Ewha Womans University, Korea) 
±³À°½Ã°£ 09-12 Room 1 13:38~13:45 Macrophage-specific PCSK9 promotes Inflammatory activation after acute myocardial infarction  Shin Hye Moon(Ewha Womans University, Korea) 
Åä·Ð 09-12 Room 1 13:45~14:10 Q&A  () 
±³À°½Ã°£ 09-12 Room 3 13:10~13:17 Intravital two-photon imaging of dynamics of hepatic lipid droplets in fasted and refed state  Jieun Moon(Korea Advanced Institute of Science and Technology, Korea) 
±³À°½Ã°£ 09-12 Room 3 13:17~13:24 Relative contributions of statin intensity, achieved LDL-C level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes  Ji Yoon Kim(Korea University, Korea) 
±³À°½Ã°£ 09-12 Room 3 13:24~13:31 Hypertriglyceridemia is an independent risk factor for cardiovascular diseases in Korean adults aged 30-49 years: a nationwide population-based study  Bo Kyung Koo(Seoul National University, Korea) 
±³À°½Ã°£ 09-12 Room 3 13:31~13:38 Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose  Chan Joo Lee(Yonsei University, Korea) 
±³À°½Ã°£ 09-12 Room 3 13:38~13:45 Association between dietary acid load and metabolic syndrome risk ?  Mi Ri Ha(Dong-A University, Korea) 
Åä·Ð 09-12 Room 3 13:45~14:10 Q&A  () 
±³À°½Ã°£ 09-12 Room 1+2+3 14:10~14:40 Targeting smooth muscle cell in management of atherosclerotic cardiovascular disease  Martin Bennett(University of Cambridge, UK) 
È޽Ġ09-12  14:40~15:00 Break  () 
±³À°½Ã°£ 09-12 Room 1 15:00~15:25 Lp(a) as a risk factor  Hiroshi Yoshida(Jikei University School of Medicine, Japan) 
±³À°½Ã°£ 09-12 Room 1 15:25~15:50 Recent results on Lp(a) therapeutics  Sotirios Tsimikas(University of California San Diego, USA) 
±³À°½Ã°£ 09-12 Room 1 15:50~16:15 Anti-inflammatory treatment to reduce CV risk  Jung Ho Heo(Kosin University, Korea) 
Åä·Ð 09-12 Room 1 16:15~16:40 Discussion  () 
±³À°½Ã°£ 09-12 Room 2 15:00~15:25 Future of CV risk stratification in FH patients  Hayato Tada(Kanazawa University, Japan) 
±³À°½Ã°£ 09-12 Room 2 15:25~15:50 Current trend in treatment of HeFH/HoFH  Dirk Blom(Hatter Institute for Cardiovascular Research in Africa, South Africa) 
±³À°½Ã°£ 09-12 Room 2 15:50~16:15 Upcoming treatment agents for FH  Sang-Hyun Kim(Seoul National University, Korea) 
Åä·Ð 09-12 Room 2 16:15~16:40 Discussion  () 
±³À°½Ã°£ 09-12 Room 3 15:00~15:25 Beyond HDL-cholesterol: the search for functional biomarkers of HDL  Arnold von Eckardstein(University of Zürich, Switzerland) 
±³À°½Ã°£ 09-12 Room 3 15:25~15:50 HDL and the cardiovascular risk in diabetes  Tomas Vaisar(University of Washington, USA) 
±³À°½Ã°£ 09-12 Room 3 15:50~16:15 What¡¯s new in HDL-modifying therapeutics?  Jang Hoon Lee(Kyungpook National University, Korea) 
Åä·Ð 09-12 Room 3 16:15~16:40 Discussion  () 
±³À°½Ã°£ 09-12 Room 4 15:00~15:25 Function of miR-33a/b in lipid and systemic metabolism  Koh Ono(Kyoto University, Japan) 
±³À°½Ã°£ 09-12 Room 4 15:25~15:50 Non-coding RNA control of cholesterol metabolism and atherosclerosis  Katey Rayner(University of Ottawa, Canada) 
±³À°½Ã°£ 09-12 Room 4 15:50~16:15 The role of non-coding RNAs in vascular smooth muscle cells  Young-Kook Kim(Chonnam National University, Korea) 
Åä·Ð 09-12 Room 4 16:15~16:40 Discussion  () 
±³À°½Ã°£ 09-12 Room 5 15:00~15:20 REvisiting lipids in REtinal diseases : a focused review on age-related macular degeneration and diabetic retinopathy  Dong Ho Park(Kyungpook National University, Korea) 
±³À°½Ã°£ 09-12 Room 5 15:20~15:40 The potential role of dyslipidemia in COVID-19 severity: an umbrella review of systematic reviews  Geun Joo Choi(Chung-Ang University, Korea) 
±³À°½Ã°£ 09-12 Room 5 15:40~16:00 Effect of breakfast consumption and meal time regularity on nutrient intake and cardiometabolic health in Korean adults  Oh Yoen Kim(Dong-a University, Korea) 
±³À°½Ã°£ 09-12 Room 5 16:00~16:20 Mesenchymal stem cell-mediated therapy of peripheral artery disease is stimulated by a lamin A-progerin binding inhibitor  Jae Ho Kim(Pusan National University, Korea) 
±³À°½Ã°£ 09-12 Room 5 16:20~16:40 Phosphorylation in novel mitochondrial creatine kinase tyrosine residues render cardioprotection against hypoxia/reoxygenation injury  Jin Han(Inje University, Korea) 
È޽Ġ09-12  16:40~16:50 Break  () 
±âŸ 09-12 ALL 16:50~17:00 Closing Remark  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ The 10th International Congress on Lipid & Atherosclerosis (ICoLA 2021) 2ÀÏÂ÷ : 2021-09-11""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼­¿ï´ëÇб³º´¿ø (¿Â¶óÀÎ) 2021 Á¦10Â÷ ¼ºÀÎôÃߺ¯Çü½ÉÆ÷Áö¾ö Adult Deformity Symposium : 2021-09-11
´ÙÀ½±Û 2021³â ´ëÇÑ°í°üÀýÇÐȸ ±¹Á¦Çмú´ëȸ(ICKHS 2021) (3ÀÏÂ÷) : 2021-09-11
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20964 °æ±â ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ 2024³âµµ Á¦27Â÷ Çмú´ëȸ(2ÀÏÂ÷) : 2024-06-21 0 3 2024-06-14
20963 Á¦ÁÖ ´ëÇѳúÇ÷°ü³»Ä¡·áÀÇÇÐȸ The 18th Annual Summer Conference on Endovascular Neurosurgical Therapy (ASCENT 2024) 1ÀÏÂ÷ : 2024-06-21 0 2 2024-06-14
20962 ¼­¿ï 2024³â ´ëÇÑÀÇ·áÁ¤º¸ÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2024-06-20 0 5 2024-06-14
20961 ¼­¿ï (¿Â¶óÀÎ) 2024³â Á¦1ȸ ¼­¿ïÀÇ·á¿ø Áö¿ª»çȸ ¿¬¼ö°­Á : 2024-06-20 0 5 2024-06-14
20960 ¼­¿ï (¿Â¶óÀÎ) 2024³â Á¦1ȸ ¼­¿ïÀÇ·á¿ø Áö¿ª»çȸ ¿¬¼ö°­Á : 2024-06-20 0 2 2024-06-14
20959 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ°øÁߺ¸°ÇÀÇ»çÇùÀÇȸ 2Â÷ ¿Â¶óÀÎ ÇÏ°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-20 0 2 2024-06-14
20958 ºÎ»ê ´ëÇѺ´¸®ÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ 6¿ù ¿¬¼ö±³À° : 2024-06-20 0 2 2024-06-14
20957 ¼­¿ï (¿Â¶óÀÎ) 2024 ÀÀ±Þ½ÉÀ忬±¸È¸ ½ÉÀüµµ ½ÉÆ÷Áö¿ò : 2024-06-20 0 2 2024-06-14
20956 ´ëÀü dizziness battle - dizziness ÀÌÇØ¿Í ½Å°æ°úÀû Ä¡·á : 2024-06-20 0 2 2024-06-14
20955 °æ±â ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ 2024³âµµ Á¦27Â÷ Çмú´ëȸ(1ÀÏÂ÷) : 2024-06-20 0 0 2024-06-14
20954 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀüÃæûÁöȸ - Á¦4Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-20 0 2 2024-06-14
20953 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ ´ëÇѺ´¸®ÇÐȸ ÁöµµÀü¹®ÀÇ ¿öÅ©¼¥ : 2024-06-19 0 2 2024-06-14
20952 ±¤ÁÖ ´ëÇÑÇǺΰúÇÐȸ Á¦172Â÷ È£³²Áöȸ : 2024-06-19 0 2 2024-06-14
20951 ¿ï»ê ´ëÇѳ»°úÇÐȸ ¿ï»êÁöȸ ¿¬¼ö°­Á : 2024-06-19 0 3 2024-06-14
20950 ´ë±¸ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ ´ë±¸°æºÏÁöȸ 2024³â 2Â÷ Áý´ãȸ : 2024-06-19 0 3 2024-06-14
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷